1. Home
  2. CRSP vs SON Comparison

CRSP vs SON Comparison

Compare CRSP & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.11

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$56.44

Market Cap

4.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
SON
Founded
2013
1899
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Containers/Packaging
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.7B
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
CRSP
SON
Price
$60.11
$56.44
Analyst Decision
Buy
Buy
Analyst Count
17
8
Target Price
$70.00
$63.00
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
05-15-2026
05-20-2026
Dividend Yield
N/A
3.79%
EPS Growth
N/A
510.30
EPS
N/A
10.07
Revenue
$289,590,000.00
$7,518,753,000.00
Revenue This Year
$1,603.19
$0.27
Revenue Next Year
$78.75
$1.94
P/E Ratio
N/A
$8.28
Revenue Growth
9169.85
41.72
52 Week Low
$30.06
$38.65
52 Week High
$78.48
$58.44

Technical Indicators

Market Signals
Indicator
CRSP
SON
Relative Strength Index (RSI) 61.24 69.09
Support Level $58.40 $43.81
Resistance Level $60.40 $58.44
Average True Range (ATR) 3.03 1.53
MACD 1.16 0.07
Stochastic Oscillator 86.78 74.07

Price Performance

Historical Comparison
CRSP
SON

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

Share on Social Networks: